{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "research-program", "type": "definition", "offset": [11, 27]}, {"key": "active-compounds", "type": "clause", "offset": [28, 44]}, {"key": "the-foregoing", "type": "clause", "offset": [331, 344]}, {"key": "licensed-compound", "type": "definition", "offset": [349, 366]}], "size": 6, "snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "samples": [{"hash": "cBlQ6dTV8Mr", "uri": "/contracts/cBlQ6dTV8Mr#licensed-compounds", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "mNHm0OY40j", "uri": "/contracts/mNHm0OY40j#licensed-compounds", "label": "Collaboration Agreement (Discovery Partners International Inc)", "score": 21.0, "published": true}, {"hash": "i3bRX4mtKZe", "uri": "/contracts/i3bRX4mtKZe#licensed-compounds", "label": "Collaboration Agreement (Infinity Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "hash": "c4d28c485812e816983f87e5c8418347", "id": 1}, {"snippet_links": [{"key": "in-combination", "type": "definition", "offset": [85, 99]}, {"key": "purpose-of-use", "type": "definition", "offset": [135, 149]}, {"key": "licensed-product", "type": "definition", "offset": [153, 169]}, {"key": "in-the-field", "type": "clause", "offset": [194, 206]}, {"key": "in-the-territory", "type": "clause", "offset": [207, 223]}], "size": 5, "snippet": "means the antiretroviral compounds known as lopinavir and ritonavir, individually or in combination, manufactured or sold for the sole purpose of use in Licensed Product solely for Exploitation in the Field in the Territory.", "samples": [{"hash": "UZK1t2cl9T", "uri": "/contracts/UZK1t2cl9T#licensed-compounds", "label": "License Agreement", "score": 35.3694419861, "published": true}, {"hash": "kE8pjttLRi6", "uri": "/contracts/kE8pjttLRi6#licensed-compounds", "label": "License Agreement", "score": 28.6865272522, "published": true}, {"hash": "ci96oYIbTyR", "uri": "/contracts/ci96oYIbTyR#licensed-compounds", "label": "License Agreement", "score": 28.5031242371, "published": true}], "hash": "8c440d371863270d27c2fdfd598b12dd", "id": 2}, {"snippet_links": [{"key": "by-either-party", "type": "clause", "offset": [66, 81]}, {"key": "respective-affiliates", "type": "definition", "offset": [100, 121]}, {"key": "third-party", "type": "clause", "offset": [129, 140]}, {"key": "working-with", "type": "definition", "offset": [141, 153]}, {"key": "such-party", "type": "clause", "offset": [170, 180]}, {"key": "of-the-parties", "type": "clause", "offset": [245, 259]}, {"key": "conduct-of-the-collaboration", "type": "clause", "offset": [267, 295]}, {"key": "exercise-of", "type": "clause", "offset": [306, 317]}, {"key": "this-agreement", "type": "clause", "offset": [346, 360]}, {"key": "prior-agreement-effective-date", "type": "definition", "offset": [380, 410]}, {"key": "target-exclusivity-period", "type": "definition", "offset": [526, 551]}, {"key": "at-any-time", "type": "clause", "offset": [636, 647]}, {"key": "prior-to-the", "type": "clause", "offset": [659, 671]}], "size": 5, "snippet": "means any EZH2 Compound(s) that is:\n(a) synthesized or identified by either Party (or by any of its respective Affiliates or any Third Party working with or on behalf of such Party or any of its respective Affiliates) or jointly by or on behalf of the Parties in the conduct of the Collaboration or in the exercise of such Party\u2019s licenses under this Agreement from and after the Prior Agreement Effective Date, excluding Compounds Controlled by either Party and first identified as EZH2 Compounds after the expiration of the Target Exclusivity Period; or\n(b) otherwise Controlled by EPIZYME as of the Prior Agreement Effective Date or at any time thereafter prior to the expiration of the Target Exclusivity Period.", "samples": [{"hash": "9m7ph8xgnbN", "uri": "/contracts/9m7ph8xgnbN#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 32.1457901001, "published": true}, {"hash": "1dS7TxoQ6Hg", "uri": "/contracts/1dS7TxoQ6Hg#licensed-compounds", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "ew6NIZCekN6", "uri": "/contracts/ew6NIZCekN6#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 26.201915741, "published": true}], "hash": "e1a054699ffba7ee01317a64e2cbbcd8", "id": 3}, {"snippet_links": [{"key": "covered-by", "type": "definition", "offset": [22, 32]}, {"key": "patent-rights", "type": "definition", "offset": [65, 78]}], "size": 5, "snippet": "means those compounds covered by the Licensed ------------------ Patent Rights.", "samples": [{"hash": "kTLHE0epyOu", "uri": "/contracts/kTLHE0epyOu#licensed-compounds", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "aWgb3DDt35L", "uri": "/contracts/aWgb3DDt35L#licensed-compounds", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "8762b7b1f742fae978689f7aa87b1f1e", "id": 4}, {"snippet_links": [{"key": "the-foregoing", "type": "clause", "offset": [339, 352]}], "size": 4, "snippet": "means (i) JCN068, (ii) any Back-up Compounds, and (iii) all prodrugs, metabolites, stereoisomers, diastereomers, enantiomers, tautomers, solvates, hydrate forms, homologs, salt forms, labeled forms (e.g., deuterated, 13C enriched, etc.), esters, crystalline forms (e.g., polymorphs), semi-crystalline forms, and amorphous forms, of any of the foregoing compounds.", "samples": [{"hash": "knxU6sgGxaf", "uri": "/contracts/knxU6sgGxaf#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 33.2245025635, "published": true}, {"hash": "4gJRxMjC6ka", "uri": "/contracts/4gJRxMjC6ka#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4798088074, "published": true}, {"hash": "f5QS7bHrhFY", "uri": "/contracts/f5QS7bHrhFY#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4360046387, "published": true}], "hash": "b3f0b895e6931677cb8b6b24c3bfba46", "id": 5}, {"snippet_links": [{"key": "lead-compound", "type": "clause", "offset": [14, 27]}, {"key": "collaboration-compounds", "type": "clause", "offset": [121, 144]}], "size": 4, "snippet": "means (a) the Lead Compound, (b) any Licensed Prothena Compounds, (c) any Licensed Roche Compounds, and (d) any Research Collaboration Compounds. [*]", "samples": [{"hash": "da9aBQllr7S", "uri": "/contracts/da9aBQllr7S#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.42710495, "published": true}, {"hash": "jWF7rQ6VTwU", "uri": "/contracts/jWF7rQ6VTwU#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.1779594421, "published": true}, {"hash": "30Bxs4KpB8O", "uri": "https://s29.q4cdn.com/936209790/files/doc_financials/2013/q4/0001559053-14-000007.pdf", "label": "s29.q4cdn.com", "score": 9.9637231827, "published": false}], "hash": "eda5353f591f28a9f18ad14149d8bcb4", "id": 6}, {"snippet_links": [], "size": 4, "snippet": "means [*****].", "samples": [{"hash": "4kdd8Fd1qYT", "uri": "/contracts/4kdd8Fd1qYT#licensed-compounds", "label": "License Agreement (AC Immune SA)", "score": 30.295003891, "published": true}, {"hash": "f6w5mEjgHqw", "uri": "/contracts/f6w5mEjgHqw#licensed-compounds", "label": "License Agreement (AC Immune SA)", "score": 30.2156066895, "published": true}], "hash": "767337c4d203ca0b6517292d5a65f517", "id": 7}, {"snippet_links": [{"key": "offer-for-sale", "type": "clause", "offset": [61, 75]}, {"key": "covered-by", "type": "definition", "offset": [94, 104]}, {"key": "university-technology", "type": "definition", "offset": [109, 130]}, {"key": "claims-of", "type": "clause", "offset": [177, 186]}, {"key": "the-patents", "type": "clause", "offset": [187, 198]}], "size": 4, "snippet": "means any individual compounds whose manufacture, use, sale, offer for sale or importation is covered by any University Technology or Niigata Technology or by one or more Valid Claims of the Patents.", "samples": [{"hash": "7NCXiDPl4vl", "uri": "/contracts/7NCXiDPl4vl#licensed-compounds", "label": "License Agreement (Panacos Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "bz0Hyu1qUcE", "uri": "https://sec.report/Document/0001193125-09-010492/0001193125-09-010492.txt", "label": "sec.report", "score": 10.1704311371, "published": false}], "hash": "1e85df4d2ece039adaae98c330e1b591", "id": 8}, {"snippet_links": [{"key": "on-schedule", "type": "definition", "offset": [56, 67]}], "size": 3, "snippet": "means collectively, (a) each of the compounds set forth on Schedule 1.53 and (b) [***].", "samples": [{"hash": "euHVHJx0G8s", "uri": "/contracts/euHVHJx0G8s#licensed-compounds", "label": "License Agreement (Sionna Therapeutics, Inc.)", "score": 36.0444908142, "published": true}, {"hash": "dGGv09mJN09", "uri": "/contracts/dGGv09mJN09#licensed-compounds", "label": "License Agreement (Sionna Therapeutics, Inc.)", "score": 35.9021224976, "published": true}, {"hash": "eLEB6NFXLvl", "uri": "/contracts/eLEB6NFXLvl#licensed-compounds", "label": "License Agreement (Sionna Therapeutics, Inc.)", "score": 35.6967811584, "published": true}], "hash": "40923283bebd4e600093e9b0f1abb77b", "id": 9}, {"snippet_links": [{"key": "the-expression", "type": "clause", "offset": [40, 54]}, {"key": "collaboration-target", "type": "clause", "offset": [62, 82]}, {"key": "research-deliverables", "type": "clause", "offset": [159, 180]}, {"key": "the-effective-date", "type": "clause", "offset": [271, 289]}, {"key": "during-the-term", "type": "clause", "offset": [293, 308]}, {"key": "to-amgen", "type": "clause", "offset": [344, 352]}], "size": 3, "snippet": "means any RNAi Molecules for inhibiting the expression of the Collaboration Target that are provided in, or optimized or modified directly from, the Arrowhead Research Deliverables and any back-up RNAi Molecules thereto that have been generated by Arrowhead on or before the Effective Date or during the Term, which RNAi Molecules are licensed to Amgen hereunder.", "samples": [{"hash": "9e65fh2TboP", "uri": "/contracts/9e65fh2TboP#licensed-compounds", "label": "Collaboration and License Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 27.9514026642, "published": true}, {"hash": "hcmDz1fbLDc", "uri": "https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_ARWR_2016.pdf", "label": "www.annualreports.com", "score": 14.9577980042, "published": false}, {"hash": "8OItKUmOpUT", "uri": "https://ir.arrowheadpharma.com/static-files/912b0a18-79e4-4197-9593-6b97ff9572f8", "label": "ir.arrowheadpharma.com", "score": 9.0807666779, "published": false}], "hash": "9b10ae6b8e46f64c6eb1ea9f979726ed", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbbGljZW5zZWQtY29tcG91bmRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 226, "snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "title": "Licensed Compounds", "id": "licensed-compounds", "examples": ["Upon Licensee\u2019s written request (which shall be at Licensee\u2019s discretion) following \u2587\u2587\u2587\u2587\u2587\u2019 receipt of the Upfront Payment in accordance with Section 6.1, Qyuns shall transfer to Licensee (or Licensee\u2019s designee) all the inventory of the <strong>Licensed Compounds</strong>, as well as all relevant materials for the manufacture of <strong>Licensed Compounds</strong> (inclusive of master cell banks, working cell banks, plasmids and reference materials), in each case, in Qyuns\u2019 possession or control existing as of the Effective Date.", "On a jurisdiction-by-jurisdiction basis, upon the expiration of the Royalty Term in such jurisdiction, the License in such jurisdiction shall become fully paid-up, royalty-free, perpetual and irrevocable under the Licensed Know-How for use with the <strong>Licensed Compounds</strong> and Licensed Product.", "From time to time during the Term, promptly following Licensee\u2019s request and at Licensee\u2019s own costs and expenses, Qyuns shall transfer to Licensee any additional Licensed Know-How that Qyuns generates or obtains after the Effective Date and that is necessary or reasonably useful to enable Licensee to Exploit the <strong>Licensed Compounds</strong> and Licensed Product.", "Within [***] days following \u2587\u2587\u2587\u2587\u2587\u2019 receipt of the Upfront Payment in accordance with Section 6.1, Qyuns shall transfer to Licensee all Licensed Know-How in existence as of the Effective Date that is necessary or reasonably useful to enable Licensee to Exploit (but excluding the Manufacture of) <strong>Licensed Compounds</strong> and Licensed Product in the Field in the Territory."], "related": [["licensed-compound", "Licensed Compound", "Licensed Compound"], ["licensed-antibody", "Licensed Antibody", "Licensed Antibody"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["licensed-products", "Licensed Products", "Licensed Products"]], "related_snippets": [], "updated": "2026-10-17T06:05:09+00:00"}, "json": true, "cursor": ""}}